Press Release

KDA Group completes previously announced sales of a majority stake in Pharmapar

Thetford Mines, Quebec – February 18, 2019 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) is pleased to announce that the transaction with Strides Pharma Canada inc. (“Strides”) previously announced in its press releases dated December 4, 2018 and February 1st, 2019, according to which Strides acquired 80% of the issued and outstanding shares of its subsidiary Pharmapar Inc. (“Pharmapar”) has been completed.

KDA Group signed a share purchase agreement with Strides for the sales of majority stake in Pharmapar

Thetford Mines, Quebec – February 1st, 2019 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) is proud to announce, as previously disclosed in its press release dated December 4, 2018, that it has entered into a share purchase agreement (the “Purchase Agreement”) with Strides Pharmaceuticals Canada Inc. (“Strides”) under which Strides agreed to acquire 80% of the issued and outstanding shares of Pharmapar Inc. (“Pharmapar”), a subsidiary of KDA specializing in the distribution of generic drugs, for four million Canadian dollars (CAN$4,000,000) (the “Sale Price”).

KDA Group announces interim Chief Financial Officer, Finance Director and appointment at its subsidiary Pharmapar Inc.

Thetford Mines, March 9, 2018 – KDA Group Inc. (TSXV: KDA) (“KDA Group” or the “Corporation”) announced today that it has accepted the resignation of its Chief Financial Officer, Mr. Bruno Dumais, effective immediately. Mr. Dumais is leaving the Corporation to pursue other interests. In the interim, Mr. Michael Kinley, Chairman of the Audit Committee, will assume theresponsibilities of Chief Financial Officer.

Groupe KDA © 2019. Tous droits réservés.